{"id":763192,"date":"2023-06-13T04:33:08","date_gmt":"2023-06-13T08:33:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-laboratories-launches-off-the-shelf-lentiviral-vector-packaging-plasmids\/"},"modified":"2023-06-13T04:33:08","modified_gmt":"2023-06-13T08:33:08","slug":"charles-river-laboratories-launches-off-the-shelf-lentiviral-vector-packaging-plasmids","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-laboratories-launches-off-the-shelf-lentiviral-vector-packaging-plasmids\/","title":{"rendered":"Charles River Laboratories Launches Off-the-Shelf Lentiviral Vector Packaging Plasmids"},"content":{"rendered":"

<\/p>\n

Charles River Laboratories Launches Off-the-Shelf Lentiviral Vector Packaging Plasmids<\/b><\/p>\n

New plasmids will help accelerate and standardize lentiviral vector development from clinical to commercial manufacturing<\/i><\/p>\n

WILMINGTON, Mass.–(BUSINESS WIRE<\/a>)–
\nCharles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf lentiviral vector (LVV) packaging plasmids, providing a streamlined solution to the challenges associated with plasmid sourcing in cell and gene therapies.<\/p>\n

\nCell and gene therapies often rely on plasmid DNA (pDNA) as a critical starting material. However, production challenges such as capacity bottlenecks and timeline pressures, as well as a need for process development optimization can result in increased lead time, cost and complexity. Charles River\u2019s off-the-shelf packaging plasmids offer an alternative solution to these hurdles with immediate availability, reduced development costs and simplified supply chains that streamline and secure lentiviral vector production.<\/p>\n

\nIn addition to its off-the-shelf offerings, Charles River provides services to meet customer specific needs such as regulatory requirements or product characteristics. These include viral vector production services ranging from clone construction through good manufacturing practice (GMP) for clinical trials or commercial use.<\/p>\n

Plasmid DNA CDMO Services<\/b><\/p>\n

\nThe addition of off-the-shelf LVV plasmids follows the launch of Charles River\u2019s pHelper plasmids<\/a> aimed at supporting AAV based gene therapy programs and eXpDNA\u2122 plasmid manufacturing platform<\/a>, established over decades of plasmid DNA CDMO scale-up experience which significantly reduces plasmid production turnaround time for advanced therapy medical product (ATMP) and vaccine developers.<\/p>\n

\nIn recent years, Charles River has significantly broadened its cell and gene therapy portfolio with several acquisitions and recent expansions<\/a> to simplify complex supply chains and meet growing global demand for plasmid DNA, viral vector, and cell therapy services. The Company offers end-to-end support and supply chain simplification for cell and gene therapy developers. Combined with the Company\u2019s legacy testing services, Charles River offers an industry-leading \u201cconcept-to-cure\u201d solution for advanced therapies.<\/p>\n

Approved Quotes<\/b><\/p>\n